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Abstract Development of colorectal cancer occurs via a
number of key pathways, with the clinicopathological features
of specific subgroups being driven by underlying molecular
changes. Mutations in key genes within the network of signal-
ling pathways have been identified; however, therapeutic
strategies to target these aberrations remain limited. As under-
standing of the biology of colorectal cancer has improved, this
has led to a move toward broader genomic testing, collabora-
tive research and innovative, adaptive clinical trial design.
Recent developments in therapy include the routine adoption
of wider mutational spectrum testing prior to use of targeted
therapies and the first promise of effective immunotherapy for
colorectal cancer patients. This review details current bio-
markers in colorectal cancer for molecular stratification and
for treatment allocation purposes, including open and planned
precision medicine trials. Advances in our understanding,
therapeutic strategy and technology will also be outlined.
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Background
Treatment of metastatic colorectal cancer (CRC) with tradi-
tional 5-fluorouracil (5FU)-based chemotherapy has been
modified, with addition of oxaliplatin, irinotecan and mono-
clonal antibodies targeting vascular endothelial growth factor
(VEGF) and the epidermal growth factor receptor (EGFR).
These modifications have led to improved overall survival
for patients to over 40 months from diagnosis [1–3].
However, considerable heterogeneity exists within CRC due
to the varied genetic and epigenetic mechanisms involved in
differing pathways of colorectal carcinogenesis [4]. Improved
understanding of common tumours, for example breast can-
cer, has resulted in stratification for prognostication and treat-
ment purposes being used for over a decade [5]. In non-small
cell lung cancer (NSCLC), single gene Bdriver^ mutations
predict for high response rates using molecularly targeted
agents [6, 7]. However, attempts to stratify CRC using clini-
copathological and molecular features for prognostic and pre-
dictive purposes have had limited success, and correlation
between subtyping strategies has been poor [8–10]. This re-
view will discuss molecularly defined subtypes of CRC and
implications for current and future patient management.
Colorectal Carcinogenesis
Fearon and Vogelstein proposed a stepwise model for colorec-
tal carcinogenesis highlighting the role of critical tumour
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suppressor genes and oncogenes in adenoma and subsequent
carcinoma development with inactivation of the adenomatous
polyposis coli (APC) tumour suppressor gene as the initiating
event [11]. This is understood to be the predominant mecha-
nism for development of CRC. Subsequently, less frequently
occurring tumourigenic pathways have been identified. The
processes have been classified as either chromosomal instabil-
ity (CIN) or mutator phenotype that includes DNA repair de-
fects and aberrant DNA methylation [4]. Characteristic geno-
mic changes are associated with each of these (Fig. 1a).
Microsatellite Instability
Protective mechanisms exist to facilitate replication of normal
cellular DNA. Genes encoding for DNA damage repair
(DDR) proteins are commonly mutated in cancer.
Dysregulation of this process permits an accumulation of so-
matic mutations and contributes to genomic instability, now
recognised as critical in cancer development and metastasis
[12]. As a pathway involved in both hereditary and sporadic
forms of CRC, the mutator phenotype with mismatch repair
deficiency (dMMR) is of particular interest.
Postreplicative mismatch repair (MMR) maintains geno-
mic stability by eliminating single-base mismatches and
insertion-deletion loops of short repeated nucleotide se-
quences (microsatellites) occurring during DNA replication
[13]. Normal interaction of critical MMR proteins comprising
MLH1, MSH2, MSH3, MSH6 and PMS2 is required for
proofreading and correction of these insertion-deletion loops.
Mutation of genes encoding for theseMMR proteins or hyper-
methylation of the MLH1 promoter causes gene silencing,
with dMMR and subsequent microsatellite instability (MSI).
Due to lack of recognition and clearance of damaged cells
during replication, dMMR status results in an accumulation
of mutations within tumour cells compared to those with pro-
ficient MMR (pMMR) or microsatellite stability (MSS) that
facilitates tumour growth [14].
TheMSI subgroup constitutes approximately 15% of CRC
overall. Germline mutation of MMR genes may occur as an
autosomal dominant syndrome termed hereditary non-
polyposis colorectal cancer (HNPCC), or Lynch syndrome,
and contributes to 2–5 % of CRC. MLH1 is most frequently
involved either by mutation in 60 % of inherited cases or
epigenetic inactivation in association with the CpG island
methylator phenotype (CIMP) [15]. MSI CRCs are more fre-
quently located in the proximal bowel, with poor differentia-
tion, mucinous subtype and dense lymphocytic infiltration,
suggestive of a strong antitumoural immune response [16].
Patients with sporadic MSI CRC are older and the tumours
are characterised by frequent BRAF (V600E) mutation and
absence of MLH1 and PMS2 proteins [17]. Loss of MLH1
expression increases with age, resulting in CRC development
in the elderly, in contrast to earlier disease presentation in
patients with Lynch syndrome [18, 19].
DNA polymerases δ and ε are involved in DNA recon-
struction following damage. Germline variants in the exonu-
clease domain of the DNA polymerases POLE and POLD1
predispose to cancer including CRC, by impairing polymerase
proofreading and greatly increasing the rate of base substitu-
tion mutations. The resulting tumour phenotype has similari-
ties to that caused by dMMR, including high immunogenicity
and favourable prognosis but with mutation burden signifi-
cantly higher than that found in MSI CRC [20, 21]. These
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Fig. 1 aGenetic models of CRC: i. Chromosomal Instability; ii. Mutator
phenotype. Stepwise carcinogenesis occurs due to differing molecular
changes in each model. b Resulting core genomic subtypes by
molecular subtyping. MMR mismatch repair, CIN chromosomal
instability, MSS microsatellite stable,MSI microsatellite instable
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are a rare subtype (0.25–1.5 % of CRC) and no therapeutic
strategies currently exist to target these specific genomic ab-
errations, although such investigation is planned (Table 1 and
Table 2).
Prognostic and Predictive Implications for MSI
MSI status has been evaluated as a prognostic biomarker in
CRC, with conferral of prognostic benefit for patients with
early MSI CRC [22]. Molecular subtyping strategies have
highlighted a lower disease-specific mortality in patients with
MSI CRC regardless of the initiating defect [23]. This benefit
appears to hold true in the adjuvant setting. However, a sub-
sequent study of patients with stage II and III disease showed
no significant difference in overall survival (OS) or
progression-free survival (PFS) due to dMMR, but demon-
strated statistically poorer OS following administration of
5FU-based chemotherapy (82.4 % compared with 89.5 %
for pMMR) [24]. It has been proposed that adjuvant 5FU-
based chemotherapy should be avoided in stage II MSI CRC
where toxicity may be prevented. Whether the addition of
oxaliplatin may abrogate the detrimental effect of 5FU for
patients with MSI CRC remains unclear [25–29]. The prog-
nostic benefit of MSI in early stage disease is lost at time of
relapse with rapid disease progression and reduced OS
[30].Given their possibly poorer response to 5FU-based che-
motherapy, use of targeted agents is of great interest in this
subgroup.
Poly [ADP-ribose] polymerase-1 (PARP-1) localizes to
sites of DNA damage and is involved in repair of these
Table 1 Selected molecular subtypes of colorectal cancer and associated clinical trials utilising targeted agents
Tumour subtype Investigative strategies Agents Phase of trial Clinicaltrials.gov
identifier
Mismatch repair deficient/microsatellite
instable
PARP inhibition Olaparib II NCT00912743
Immune checkpoint inhibition (PD-L1) Durvalumab (MEDI4736) II NCT02227667
Immune checkpoint inhibition (PD-L1) Atezolizumab (MPDL3280A) II NCT02291289
Immune checkpoint inhibition (PD-1) Nivolumab ± Ipilimumab I/II NCT02060188
Immune checkpoint inhibition (PD-1) Pembrolizumab (MK-3475) II NCT02460198
± standard chemotherapy III NCT02563002
RAS mutation Pan-RAF inhibition BMS-908662 ±Cetuximab I/II NCT01086267
AKT and MEK inhibition MK-2206 and AZD6244 (Selumetinib) II NCT01333475
HDAC inhibition 4SC-201 (Resminostat) + FOLFIRI II NCT01277406
ERK inhibition CC-90003 I NCT02313012
NOTCH inhibition RO4929097 +Cetuximab I NCT01198535
MEK and MET inhibition PD-0325901+Crizotinib I NCT02510001
Multikinase inhibition Regorafenib II NCT02175654
MEK and BCL2 inhibition Trametinib and Navitoclax
(ABT-263)
I/II NCT02079740
PI3K and MEK inhibition BKM120 +MEK162 I NCT01363232
Resistant to EGFR inhibition RAF inhibition BMS-908662 ±Cetuximab I/II NCT01086267
NOTCH inhibition RO4929097 +Cetuximab I NCT01198535
BRAF mutation PI3K and MEK inhibition BKM120 +MEK162 I NCT01363232
BEZ235+MEK162 I NCT01337765
BRAF, MEK and EGFR inhibition Trametanib, Dabrafenib + Panitumumab II NCT01750918
RAF inhibition BMS-908662 ± cetuximab I/II NCT01086267
BRAF and EGFR inhibition Irinotecan, Cetuximab +Vemurafenib II NCT02164916
BRAF, PI3K and EGFR inhibition LGX818, BYL719, and Cetuximab I/II NCT01719380
BRAF, WNT and EGFR inhibition LGX818, WNT974 and Cetuximab I/II NCT02278133
ERK inhibition BVD-523 I NCT02313012
ERK inhibition CC-90003 I NCT02313012
PI3K mutation/PTEN depletion MEK and PI3K/mTOR inhibition Pimasertib + SAR245409 I NCT01390818
AKT and MEK inhibition MK-2206 and AZD6244 (selumetinib) II NCT01333475
HER2 amplification HER2 dual inhibition Trastuzumab+ Lapatinib II EudraCT Number:
2012-002128-
33
Trastuzumab+ Pertuzumab II
MET amplification MEK and MET inhibition PD-0325901+Crizotinib I NCT02510001
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defects. In MLH1- and MSH3-deficient CRC cell lines, the
combination of PARP inhibition and irinotecan therapy was
more effective than in those with functional MLH1 [31, 32].
Consequently, there is interest in use of PARP inhibition for
treatment of MSI CRC (Table 1).
Lymphocytic infiltration as a characteristic feature of MSI
CRC has prompted further investigation due to the increasing
availability of effective immunotherapies. The reasons for this
immunogenic phenotype are unclear. However, it is postulated
that this may occur due to the creation of tumour-specific
neoantigens during accumulation of mutations [33].
Analysis of primary tumour tissue from this patient subset
identified high levels of infiltration of activated CD8+ cyto-
toxic T-cells and activated Th1 cells with interferon-γ (IFNγ)
and T-box expressed in T cells (TBET), a Th1 transcription
factor. In addition, upregulated expression of the immune
checkpoints cytotoxic T lymphocyte-associated antigen 4
(CTLA4), programmed cell-death-1 (PD-1), programmed
cell-death ligand-1 (PD-L1), lymphocyte activation gene 3
(LAG3) and indoleamine 2,3-dioxygenase (IDO) was noted
in MSI tumours [34•]. The critical role of the immune system
in tumour regulation has been widely highlighted [12] and
lymphocytic infiltration in CRC is associated with lower rate
of relapse and improved prognosis [35]. Current immunother-
apeutic strategies incorporate antibodies to directly inhibit the
CTLA4 and PD-1 pathways. Use of the PD-1 inhibitor
pembrolizumab has been associated with responses in patients
with MSI CRC [36••]. Further studies of immune checkpoint
inhibitors are ongoing in this patient population (Table 1).
Individual Somatic Mutations
RAS Mutation
The mitogen-activated protein kinase (MAPK) pathway com-
prised of the RAS-RAF-MEK-ERK signalling cascade is
deregulated due to somatic gene mutation in >50 % of CRC,
with 40 % of these due to activating mutations in KRAS [37].
This pathway lies downstream of the epidermal growth factor
receptor (EGFR). Activating mutations in this pathway will
result in transcription of the gene for transforming growth
factor-α (TGFα), a ligand of the EGFR. This creates an auto-
crine signalling loop that contributes to tumoural resistance to
the anti-EGFRmonoclonal antibodies (mAbs), cetuximab and
panitumumab [38]. In combination with chemotherapy, these
therapies are the only approved biomarker-driven therapies
currently licensed for treatment of CRC and have extended
survival up to 41.3 months in patients with tumours wild type
(WT) forKRAS andNRAS [3, 39]. However, despite improved
survival for a subset of patients, no benefit is seen for those
with KRAS/NRASmutated tumours. Absence of this mutation
is not an accurate predictor of response, as only 40–50 % of
patients with KRAS/NRAS WT disease respond to the anti-
EGFR monoclonal mAbs [40]. Binding of amphiregulin
(AREG) and epiregulin (EREG) ligands to the EGFR stimu-
late mitogenesis [41]. In KRAS WT CRC, high expression of
AREG and EREG messenger RNA (mRNA) is predictive of
improved response rate, progression-free survival and overall
survival in patients treated with cetuximab [42–44]. High
EREG mRNA expression levels may predict for response in
patients irrespective of EGFR mutation status [44]. However,
these biomarkers are not validated for use in clinical practice.
Initially, mutations conferring resistance to anti-EGFR
mAbs were identified in codons 12 and 13 of exon 2 of the
KRAS gene. However, retrospective analysis of multiple trials
demonstrated the presence of further resistance mutations in
exons 2, 3 and 4 of KRAS/NRAS, resulting in a recommenda-
tion to utilise wider RAS mutational testing prior to treatment
selection and inclusion in the license for panitumumab and
cetuximab [45]. The KRAS G13D mutation conveys sensitiv-
ity to EGFR inhibitors in preclinical models, and retrospective
clinical reports suggested possible treatment benefit with
cetuximab similar to KRAS wild-type CRC. However, the
prospective international ICECREAM trial recently con-
firmed lack of efficacy of cetuximab in this molecular sub-
group [46].
Acquired mechanisms of resistance may limit treatment
efficacy of EGFR inhibitors. Use of circulating tumour DNA
(ctDNA) has identified emergence of RAS mutations follow-
ing cetuximab administration, conferring resistance to EGFR-
targeted therapy. Interestingly, introduction of an MEK
Table 2 FOCUS4 trial cohorts:
an example of a trial designed
with treatment stratification based
on molecular subtyping within
colorectal cancer
Study arm Molecular aberration Treatment
FOCUS-A BRAF mutation EGFR/BRAF/MEK inhibitors
vs observation
FOCUS-B PIK3CA mutation Aspirin vs placebo
FOCUS-C P53 and RAS dual mutation or H3K36me3 loss WEE1 inhibitor vs placebo
FOCUS-D BRAF/RAS/PI3KCAWT and no PTEN loss HER-1, 2, 3 inhibitor vs placebo
FOCUS-E Mismatch repair deficiency or POLD1/POLE mutations PD-L1 inhibitor vs placebo
FOCUS-F ATM loss ATR inhibitor vs placebo
FOCUS-N No other cohort available Capecitabine vs observation
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inhibitor in combination with cetuximab resensitised the tu-
mour to anti-EGFR therapy [47].
A number of other primary resistance mechanisms against
anti-EGFR mAbs exist, including downstream activation of
BRAF andMEK. In addition, EGFR activation may occur via
an alternate signalling pathway within the interlinked RAS-
MAPK-PI3K or may be mediated by type 1 insulin-like
growth factor receptor (IGF-1R). Reduced affinity of the
EGFR ligand or mutations within the gene, resulting in a con-
formational change to the binding site, may also physically
impair the ability of the monoclonal antibody to effectively
bind to and inhibit activation of the EGFR [48]. Based upon
preclinical research demonstrating HER2 as a resistance path-
way to EGFR inhibitors, the HERACLES trial investigates
dual inhibition of the HER2 pathway and the efficacy of dual
HER2 targeting in patient-derived xenografts [49]. The rate of
HER2 positivity was 5.4 % in the first cohort, with a 34 %
response rate and 44 % stable disease from trastuzumab and
lapatinib in 23 patients. Trials investigating additional targeted
agents aimed at reducing resistance to anti-EGFR inhibitors
are currently underway (Table 1).
Due to the relative frequency of RASmutation in CRC and
its use as a negative predictor for current molecularly stratified
treatment, identification of an effective therapy to target this
subgroup has potential clinical benefit. Treatment directed at
RAS mutated CRC has been targeted against downstream
MEK signalling, but has been less successful than treatment
for KRAS WT disease. Inhibition of MEK signalling may
cause upregulation of signalling via the PI3K-AKT-mTOR
pathway [50]. RAS is also an oncogenic driver of the PI3K-
AKT-mTOR pathway, providing rationale for the combination
of RAS andMEK pathway inhibition as a potential therapeutic
strategy (Table 1).
BRAF Mutation
An additional activating mutation implicated in tumourigenesis
within the MAPK signalling cascade is BRAF V600E muta-
tion. This occurs in 8–10 % of CRC, very rarely occurs in
conjunction with RAS mutations, and confers resistance to
anti-EGFR therapy [51]. Patients with these tumours have a
poor prognosis in the metastatic setting with aggressive tumour
biology. This mutation is strongly associated with sporadic
MSI CRC [30]. Targeted BRAF blockade using single-agent
tyrosine kinase inhibition was attempted for this disease sub-
type. However, this approach was unsuccessful, with preclini-
cal data suggesting therapeutic failure was due to aberrant up-
stream signalling via MEK and activation of the PTEN-PI3K-
AKT pathway [52]. It was further demonstrated that BRAF-
mutated cells acquired resistance to vemurafenib by stimulation
of EGFR, thereby perpetuating cell proliferation [53•]. Based
upon these findings, a triple combination of targeted agents
concurrently inhibiting BRAF, MEK and EGFR is currently
under investigation for treatment of BRAF-mutant CRC
(Table 1.). Other approaches undergoing trials include use of
ERK inhibitors and combinations of irinotecan, BRAF and
EGFR inhibitors; BRAF, EGFR and PI3K inhibitors; BRAF,
EGFR and WNT pathway inhibitors and FOLFOXIRI with
bevacizumab.
PIK3CA and PTEN
Resistance to EGFR inhibition may also be driven by the
PI3K-PTEN-AKT pathway. PI3K signalling is negatively reg-
ulated by PTEN, and may be activated by PIK3CA mutation.
This gene encodes for the catalytic subunit of PI3K and is
present in 10–18%CRC. However, activation of this pathway
may also occur due to loss of PTEN expression in 30 % CRC.
KRAS and PIK3CA mutation frequently coexist, with activa-
tion of parallel pathways in a single tumour. Similar to MEK
inhibition, single-agent targeting of this pathway has demon-
strated lack of activity due to development of resistance feed-
back loops [50]. Early phase clinical trials are investigating the
combination of MEK inhibition with AKT, PI3K and mTOR
inhibition, but results to date have been disappointing (Table
1).
Interestingly, retrospective analysis of aspirin use in pa-
tients with established CRC identified the subgroup of pa-
tients with PIK3CA exon 9 and 20 mutations as deriving a
survival benefit [54]. Although the reason for this interaction
remains poorly understood, this may provide a clinical utility
of this genomic biomarker. Aspirin is being prospectively in-
vestigated in this subgroup in the UK in the FOCUS4 trial
(first-line setting for metastatic disease) and in the adjuvant
Add-Aspirin trial (stage II/III CRC).
MET Gene
The mesenchymal-epithelial transition (MET) proto-
oncogene encodes for c-MET, a receptor with tyrosine-
kinase activity targeting hepatocyte growth factor
(HGF). Activation of this pathway has been implicated
in metastatic progression of CRC. EGFR and MET are
coexpressed in CRC and MET activation has been impli-
cated in resistance to the anti-EGFR mAb cetuximab [55].
c-MET is overexpressed in 50–60 %, amplified in 10 %
and mutated in 5 % CRC [56, 57]. The MET inhibitor
crizotinib was trialled as a single agent for treatment of
MET-amplified CRC as part of The French National AcSé
programme. However, 0/13 CRC patients with MET am-
plification derived clinical benefit from this agent [58].
Based upon preclinical work demonstrating synergistic
activity in CRC between MEK and MET inhibitors [59],
the MErCuRIC1 study is investigating the combination of
the MEK inhibitor PD-0325901 and crizotinib in patients
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with KRAS mutant, or KRAS WT, MET-amplified CRC
(Table 1).
ALK/ROS1 Translocations
The EML4-ALK fusion gene is produced by inversion in the
short arm of chromosome 2, where anaplastic large-cell lym-
phoma kinase (ALK) joins echinoderm microtubule-
associated protein-like 4(EML4), resulting in a chimeric pro-
tein with constitutive ALK activity [60]. ROS1 is an orphan
receptor tyrosine kinase phylogenetically related to ALK [61].
These carcinogenic chromosomal translocations are found in
5 % of NSCLC, where the targeted ALK, ROS1 and MET
inhibitor crizotinib has been used with up to 74 % response
rates [62, 63]. In CRC, ALK or ROS1, gene rearrangements
have not been extensively studied. Several papers have de-
tailed a unique subpopulation of between 0.8–2.5 % patients
with metastatic CRC (mCRC) with either ALK or ROS1 rear-
rangement of their tumour [64, 65]. Due to small patient num-
bers and inconsistent and expensive testing methods for ROS1
translocations, developing a clinical trial of targeted therapy
for this patient subset poses considerable challenges.
Defining Molecular Subtypes in CRC: Gene
Expression Profiling
Molecular subtyping of CRC has presented challenges,
resulting in inconsistencies within the literature with regard
to understanding of prognostic and predictive biomarkers.
This may reflect the heterogeneity of CRC, possibly due to
the lack of exclusivity outlined between the major pathways
driving carcinogenesis and disease progression. Using gene
expression profiling, the function of multiple genes can be
assessed simultaneously to give a clearer picture of the com-
plex characteristics underlying disease and reflecting genetic
and epigenetic regulation. This technique may ensure a more
informative result in addition to reducing the time for molec-
ular testing and potentially has cost-saving implications for
clinical practice.
Early-Stage Disease
A number of gene expression profiling tools have been vali-
dated for clinical use to inform prognosis in stage II CRC,
where the benefit for chemotherapy remains unclear [66].
Oncotype DX and ColDx were developed using formalin-
fixed paraffin-embedded (FFPE) tumours, and ColoPrint used
fresh frozen tissue [67–69]. Oncotype DX utilises a 12-gene
signature comprising genes associated with recurrence and
with clinical benefit to 5FU to stratify tumours into low-,
medium- or high-risk for recurrence [67]. The ColDx (now
called GeneFX colon) signature comprises a 634-gene
signature which differentiates stage II tumours into low- and
high-risk for recurrence. The hazard ratio for cancer-related
death at 5 years was 2.21, and the test performed better than
use of traditional clinicopathological variables [68]. ColoPrint
uses an 18-gene signature to classify patients with stage II
disease as high- or low-risk of recurrence and improved the
accuracy of clinicopathological variables alone for prediction
of low-risk CRC [69]. Practical difficulties with obtaining
fresh frozen tissue may limit use of this assay in routine clin-
ical practice.
Advanced Disease
Independent investigator groups have used gene expression
profiles to identify intrinsic molecular subtypes [8, 10, 70,
71]. Due to poor agreement across the resulting subtypes for
several gene expression profiles, members of the Colorectal
Cancer Subtyping Consortium agreed to combine their geno-
mic datasets to generate a consensus molecular subtyping
strategy (CMS) by applying unsupervised clustering tech-
niques to 4151 samples [72••]. From this, four subsets have
been established. CMS1 comprised 14 % of the patients and
classified older, female patients with hypermutated MSI tu-
mours demonstrating BRAF mutation and immune activation.
This is consistent with the established MSI phenotype. CMS2
was the most common subset comprising 37 %. These MSS
tumours displayed CIN, strong WNT/MYC pathway activa-
tion, TP53mutation and EGFR amplification/overexpression.
These tumours were associated with a better OS and predom-
inantly originated in the left colon. Tumours clustering as
CMS3 were associated with low CIN, moderate WNT/MYC
pathway activation. KRAS and PIK3CA mutation was com-
monly found among this subtype, as was IGFBP2 overexpres-
sion. This subset was seen in 13 % and was associated with
intermediate survival. Finally, 23 % of the tumours clustered
to CMS4. These were CIN/MSI heterogeneous, demonstrat-
ing mesenchymal/TGF-beta activation and NOTCH3/
VEGFR2 overexpression. These patients were diagnosed at
a younger age and had poorer survival outcomes. A subgroup
(13 %) that remained unclassified was also identified, with no
common features among these tumour tissues, and the authors
suggest that these may represent a transitional phenotype or
intratumoural heterogeneity. Although not a therapeutic
stratifier (as it is not possible to classify individual patient
tumours into these subtypes prospectively), this large dataset
has facilitated greater understanding of the broad biological
groups within CRC (Fig. 1b).
Antiangiogenic Agents
There are now five antiangiogenic agents licensed for use in
CRC, but empirical use of these drugs without selection con-
tributes to underwhelming levels of efficacy. There is still no
146 Curr Colorectal Cancer Rep (2016) 12:141–150
validated biomarker to predict benefit from these agents either
as monotherapy or in addition to chemotherapy, despite al-
most two decades of investigation. A 63-gene signature has
recently been shown to predict sensitivity to antiangiogenic
therapy in ovarian cancer using FFPE tumour material and is
currently being explored in CRC [73].
Innovative Clinical Trial Design
With the development of novel treatment strategies for sub-
groups of patients with CRC, finding the optimal biomarker
and ensuring appropriate targeted therapy without exhausting
limited diagnostic tissue is becoming increasingly challeng-
ing. A number of trials address this issue using a basket design
to stratify patients into the appropriate arm for therapy based
upon the molecular characteristics of the tumour at point of
testing.
The UK-based FOCUS4 study is an adaptive, biomarker-
driven, multiarm, multistage trial designed to enable stratifi-
cation of therapy for patients with mCRC during first-line
chemotherapy (see http://www.focus4trial.org). By
prospectively analysing diagnostic tumour samples for
predefined biomarkers, patients with responding or stable
disease following 16 weeks of first-line chemotherapy can
be allocated to an appropriate treatment arm. The aim of this
study is to assess response of targeted treatment strategies
using novel or repurposed agents in these molecularly
enriched cohorts. There is a hierarchy of biomarker-defined
cohorts (Table 2) [74••].
MODUL is a randomised, multicentre, controlled, open-
label, parallel-group study sponsored by Roche/Genentech
that is investigating the efficacy and safety of biomarker-
driven maintenance treatment for first-line mCRC after
16 weeks of induction of FOLFOX and bevacizumab [75].
Patients with BRAF mutations are randomised between
fluoropyrimidine (+/−bevacizumab) maintenance and the
same with addition of BRAF and EGFR inhibitors; BRAF
WT patients are randomised between fluoropyrimidine
(+/−bevacizumab) maintenance and the same with addition
of a PD-L1 inhibitor.
A similar precision medicine approach is planned in the
USA in second-line treatment of CRC in the ASSIGN trial
[76]. Here, molecularly defined subgroups based on metasta-
tic site biopsies will be randomised between targeted agents
and chemotherapy, dependent on the availability of therapies
at the time that the study opens. Current plans are to investi-
gate novel EGFR pathway targeting agents in Ball WT^ CRC,
BRAF inhibitors in BRAF-mutant CRC, targeted agents in
those with ALK/ROS-1 translocations, PI3K inhibitors in
those with PTEN loss, HER-2 inhibitors or TDM-1 in those
with HER-2 over-expression and immune checkpoint inhibi-
tors in those with MSI.
Screening Patients for Efficient Clinical Trial Access in
advanced colorectal cancer (SPECTAcolor) is an EORTC ini-
tiative launched in 2013, comprising a network of collaborat-
ing European institutions treating patients with CRC. Tumour
tissue from participants is processed for centralised, high-
throughput screening for driver mutations including KRAS,
NRAS, BRAF and PIK3CA, in addition to immunohistochem-
ical staining for MSI. Next-generation sequencing will also be
performed for 360 key cancer genes, with a view towards
enrolment in Bdownstream^ targeted multinational clinical tri-
als [77]. These and similar mutational screening platforms are
designed to optimise use of potentially small tissue samples in
order to provide a variety of appropriately targeted additional
treatment options for patients with mCRC.
Tumour Heterogeneity
Decisions regarding therapeutic strategy are currently
made using available tissue, most commonly from the
primary tumour at the time of diagnosis. During progres-
sion of malignant disease, by a process of clonal evolu-
tion, molecular differences may occur between primary
tumours and metastatic disease. This may render applica-
tion of a biomarker to a primary tumour sample inaccu-
rate for the purposes of targeted therapy for more ad-
vanced disease, with a lack of knowledge of the wider
tumour landscape [78••]. For the clinically relevant driv-
er genes, including KRAS, NRAS, BRAF, PIK3CA and
TP53, concordance between tumour primary and meta-
static disease site has been shown to be >90 % in CRC
[79•]. There appears to be less concordance for PTEN
expression by IHC, varying from 47 to 98 % between
primary and metastatic site, reducing utility of this geno-
mic marker in clinical practice [80]. Less is known about
the MSI subgroup where a baseline genomically unstable
tumour may become increasingly hypermutated during
disease progression.
The liquid biopsy is a minimally invasive sampling
technique utilising circulating cell-free (cf) DNA to reflect
the dynamic nature of clonal evolution, thereby potentially
eliminating inaccuracies in current molecular status of the
tumour while minimising discomfort and risk to the pa-
tient [81]. Its potential utility in CRC has been demon-
strated for KRAS and BRAF mutation identification during
treatment [82•].
CRC has been highlighted as one of the tumour types
where development of this technology has been identified as
a priority. Techniques to optimise laboratory procedures for
analysis and interpretation of results are currently being inves-
tigated [83]. However, validation of this exciting technology
is required prior to routine clinical adoption.
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Conclusion
Although unique subtypes within CRC have been identi-
fied, critical questions remain regarding the pathogenesis
and biology of these tumours, and optimal biomarkers
with evidence-based therapeutic strategies remain elusive.
The emergence of immunotherapy for treatment of malig-
nancy has widened treatment options for many patients,
but trials for patients with CRC are limited and are cur-
rently focused largely on those with metastatic MSI dis-
ease. The biological features of this subgroup with im-
mune infiltration as a key feature of tumourigenesis would
appear to validate this choice. However, the mechanisms
underlying poor prognosis for these patients remain incom-
pletely understood. In order to progress management of
this disease, it is critical that we understand the resistance
mechanisms to therapy and address these in developing
the next generation of therapeutic strategies. Optimising
use of EGFR inhibitors, improving treatment for those
patients with RAS and RAF mutations where no proven
targeted therapy exists, and for those with RAS/RAF WT
disease resistant to EGFR inhibition, are key areas of un-
met clinical need.
Enhancing our understanding of the CRC disease process
may result in better use and scheduling of systemic treatment,
reducing morbidity and mortality in this disease.
Development of robust and validated biomarkers will be at
the core of personalised therapy, and the novel trial designs
currently underway will aim to rapidly isolate subpopulations
for treatment while ensuring efficient use of limited tissue
resources. In addition, collaboration between multiple centres
will facilitate information sharing and generate more rapid
trial accrual to answer these clinical questions. Although bio-
markers are validated for prediction of benefit for chemother-
apy in the adjuvant setting, targeted therapy has not yet dem-
onstrated any benefit in early disease. Finally, through inter-
rogation of the molecular and immune characteristics driving
progression from adenoma to carcinoma, there is also poten-
tial for preventative measures to be explored.
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